Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interaction between FK 506 and cyclosporine in dogs.

Literature DB >> 1721281

Interaction between FK 506 and cyclosporine in dogs.

Y M Wu¹, R Venkataramanan, M Suzuki, Y Zhu, H Abdallah, J Emeigh, G J Burckart, V S Warty, J J Fung, S Todo.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Cyclosporine
Tacrolimus

Year: 1991 PMID： 1721281 PMCID： PMC2975952

Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066

× No keyword cloud information.

11 in total

1. The effect of FK 506 and CyA on the Lewis rat renal ischemia model.

Authors: M A Nalesnik; H S Lai; N Murase; S Todo; T E Starzl
Journal: Transplant Proc Date: 1990-02 Impact factor: 1.066

2. FK 506 inhibition of cyclosporine metabolism by human liver microsomes.

Authors: G Omar; I A Shah; A W Thomson; P H Whiting; M D Burke
Journal: Transplant Proc Date: 1991-02 Impact factor: 1.066

3. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors: T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal: Transplant Proc Date: 1987-02 Impact factor: 1.066

4. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

Authors: A Zeevi; R Duquesnoy; G Eiras; H Rabinowich; S Todo; L Makowka; T E Starzl
Journal: Transplant Proc Date: 1987-10 Impact factor: 1.066

5. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors: T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal: J Antibiot (Tokyo) Date: 1987-09 Impact factor: 2.649

6. Biopharmaceutical aspects of FK-506.

Authors: R Venkataramanan; V S Warty; M A Zemaitis; A T Sanghvi; G J Burckart; H Seltman; S Todo; L Makowka; T E Starzl
Journal: Transplant Proc Date: 1987-10 Impact factor: 1.066

7. The question of FK 506 nephrotoxicity after liver transplantation.

Authors: J McCauley; S Takaya; J Fung; A Tzakis; K Abu-Elmagd; A Jain; S Todo; T E Starzl
Journal: Transplant Proc Date: 1991-02 Impact factor: 1.066

8. Cyclosporine kinetics in renal transplantation.

Authors: R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal: Clin Pharmacol Ther Date: 1985-09 Impact factor: 6.875

9. Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes.

Authors: P Bertault-Peres; C Bonfils; G Fabre; S Just; J P Cano; P Maurel
Journal: Drug Metab Dispos Date: 1987 May-Jun Impact factor: 3.922

Interaction between FK 506 and cyclosporine in dogs.

1. The effect of FK 506 and CyA on the Lewis rat renal ischemia model.

2. FK 506 inhibition of cyclosporine metabolism by human liver microsomes.

3. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

4. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

5. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

6. Biopharmaceutical aspects of FK-506.

7. The question of FK 506 nephrotoxicity after liver transplantation.

8. Cyclosporine kinetics in renal transplantation.

9. Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes.

10. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

1. Pharmacokinetics of FK 506 in transplant patients.

Review 2. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Review 3. Clinical pharmacokinetics of tacrolimus.

Review 4. Mechanisms of clinically relevant drug interactions associated with tacrolimus.